Micro-Cap Index Close: August 6, 2026 — Seven Benchmarks, One Ugly Day for Earnings Losers

Micro-Cap Index Close: August 6, 2026 — Seven Benchmarks, One Ugly Day for Earnings Losers

After a blistering July that saw the Russell Microcap Index gain 58.5% over the trailing twelve months through June 30, the micro-cap market took a breather on August 6. The broader market sold off on chipmaker weakness and mixed earnings, with the S&P 500 closing down 0.16%, the Nasdaq 100 down 0.37%, the Dow Jones down 0.85%, and the Russell 2000 down 0.51%.

But behind those headline numbers, the micro-cap landscape told a more interesting story — one of earnings-driven carnage among small companies reporting Q2 results, offset by selective breakouts in financials and biotech. Here's how the seven benchmark indexes we profiled in our Micro-Cap Index Landscape piece performed, along with the five biggest micro-cap winners and losers of the session.

The Seven Benchmarks: Where They Stand

The seven indexes we track span U.S. domestic micro-caps, Canadian venture listings, and global developed and emerging market micro-caps. Here's the latest available data through August 6, 2026:

#	Index	Latest Level	1-Day Change	YTD / 1-Yr Return	Notes
1	Russell Microcap Index	1,245.90 (price) / 5,616.75 (TR)	+2.50% (Aug 4) / +1.97% (Aug 5 TR)	1-Yr: +58.5% (through 6/30/26)	The U.S. micro-cap benchmark. Semi-annual reconstitution in 2026. Up over 58% trailing one year.
2	Dow Jones Select Micro-Cap Index	$94.88 (FDM ETF NAV)	+1.68% (Aug 4)	YTD: +19.79%	Tracks liquid, fundamentally strong U.S. micro-caps. FDM ETF is the primary vehicle.
3	MSCI USA Micro Cap Index	~4,256 (est.)	+1.0% (recent session)	Monthly data	U.S. domestic micro-cap segment. MSCI August index review scheduled for Aug 12 — potential constituent changes.
4	S&P/TSX Venture Composite	923.83	+2.77% (+24.94)	1-Yr: +18.04%	Canadian venture exchange. 52-week range: 763.93 – 1,177.21. Strong recent rally in mining and resource names.
5	MSCI World Micro Cap Index	—	-0.81% (1-month, July 31)	Monthly data	Developed-markets micro-caps. Slightly negative over the past month, lagging U.S.-only benchmarks.
6	MSCI ACWI Micro Cap Index	—	—	Monthly data	Broadest global micro-cap benchmark (developed + emerging). Data reported monthly by MSCI.
7	FTSE Global Total Cap Index	—	—	~17,000 constituents	Not a pure micro-cap index — covers large to micro across global markets. Broadest investable equity universe.

Note: Several MSCI and FTSE indexes report on a monthly or delayed basis. The U.S.-listed indexes (Russell, Dow Jones) and S&P/TSX Venture provide daily data. Index levels reflect the most recent available close as of August 6, 2026.

The Takeaway: U.S. Micro-Caps Still Leading

The data confirms what we've been tracking all year: U.S. micro-cap indexes are outpacing their global counterparts. The Russell Microcap's 58.5% one-year return dwarfs the S&P/TSX Venture's 18.04% and the MSCI World Micro Cap's modest monthly decline. The Dow Jones Select Micro-Cap Index, which filters for liquidity and fundamentals, is up 19.79% YTD — strong, but trailing the Russell's more aggressive gain.

Today's broader market pullback (S&P -0.16%, Russell 2000 -0.51%) suggests the micro-cap indexes likely took a modest breather after their recent rally. But the real action wasn't at the index level — it was in the individual names reporting earnings.

Top 5 Micro-Cap Winners — August 6, 2026

Today's micro-cap gainers ($50M–$500M market cap) were concentrated in financials and biotech, with several names posting double-digit moves on earnings catalysts:

#	Ticker	Company	% Change	Market Cap	Catalyst
1	ZTG	Zenta Group	+47.79%	$118.68M	Nasdaq-listed company continuing volatile post-IPO trading; YTD return now 244.7%
2	OPRT	Oportun Financial	+32.84%	$369.90M	Q2 earnings beat: net income $8.5M, Adjusted EBITDA $48.6M, raised 2026 EBITDA guidance, cut cost of debt to 6.3%
3	WHWK	Whitehawk Therapeutics	+15.48%	$252.78M	Biotech rally on no specific news; potential sector sympathy with Iovance's 43% surge on Amtagvi Q2 beat
4	DVLV	Datavault AI	+11.89%	$270.44M	AI/data infrastructure name; continued momentum in AI-adjacent micro-caps
5	CEPL	Capstone Energy+	+7.47%	$269.33M	Energy sector micro-cap; rallied alongside broader energy strength

The standout: Oportun Financial (OPRT) was the highest-quality move of the day. The consumer lender reported Q2 net income of $8.5 million and Adjusted EBITDA of $48.6 million, beating estimates and raising full-year EBITDA guidance. The company also cut its cost of debt to 6.3% — a meaningful operational improvement for a lender. At $369.90 million market cap, OPRT is right in the micro-cap sweet spot, and the 32.84% surge was earnings-driven, not promotional.

Top 5 Micro-Cap Losers — August 6, 2026

The losers' list tells a different story — one of earnings disappointments and guidance cuts hitting micro-cap stocks disproportionately hard:

#	Ticker	Company	% Change	Market Cap	Catalyst
1	TDUP	ThredUp	-50.48%	$401.32M	Q2 earnings: revenue of $90.8M (+17% YoY) beat, but company dropped full-year revenue guidance. Guidance cut is what killed the stock.
2	CMRC	Commerce.com	-31.96%	$191.43M	Sell-off on heavy volume (6M shares); no immediate news catalyst identified
3	EBS	Emergent BioSolutions	-29.58%	$272.40M	Q2 net loss of $180.2M; lowered 2026 revenue guidance. Anthrax vaccine contracts remain a concern.
4	INSG	Inseego	-28.60%	$86.35M	Continued sell-off; 5G/IoT hardware maker under pressure from competitive concerns
5	BTMD	biote Corp	-27.88%	$57.95M	Medical aesthetics company under pressure; no immediate news catalyst

The standout: ThredUp (TDUP) is the cautionary tale of the day. The secondhand fashion marketplace posted record quarterly revenue of $90.8 million — up 17% year over year — and beat on EPS. But the company cut its full-year revenue guidance, and the market responded by cutting the stock in half. At $401.32M market cap, TDUP was near the upper edge of the micro-cap range. Today's 50% drop puts it at roughly $200M — squarely back in the middle of the range and a stark reminder that in micro-cap land, guidance matters more than the print.

What Today's Action Tells Us

Three takeaways from the August 6 session:

1. Earnings season is the great separator. The stocks moving 20-50% in a single session are almost all reporting Q2 results. Oportun beat and raised — up 33%. ThredUp beat but cut guidance — down 50%. In micro-cap, the guidance line matters more than the headline number.
2. U.S. micro-caps still lead globally. Even with today's modest pullback, the Russell Microcap's 58.5% one-year return and the Dow Jones Select MicroCap's 19.79% YTD return both outpace the S&P/TSX Venture (+18.04% 1-year) and the MSCI World Micro Cap (negative 1-month return). The U.S. micro-cap rally that began in Q2 2025 remains intact.
3. Biotech earnings drove the extremes. Iovance (IOVA) — which sits just above the micro-cap range at $2.77B — surged 43% on a blowout Q2 powered by Amtagvi. The halo effect touched smaller biotechs like Whitehawk Therapeutics (+15.48%). Meanwhile, Emergent BioSolutions (-29.58%) showed what happens when a biotech misses on guidance.

Scoring

Metric	Score	Assessment
Asset Quality / Execution	6 / 10	This is a market data recap, not a company analysis. The score reflects the quality of the data and analysis: seven index benchmarks tracked, five winners and five losers identified with market caps and catalysts. Deductions for monthly reporting gaps on MSCI and FTSE indexes.
Promotion Intensity	2 / 10	This is straight market reporting — no promotional angle, no issuer involvement. The data speaks for itself.

Quadrant: Hidden Value / Deep Value

Market data and index tracking — informational content with minimal promotion. The value is in the data itself.

Scoring Guide

Metric	What It Measures	Score Range
Asset Quality / Execution	Tangible, derisked milestones: clinical data, resource estimates, cash position, institutional backing, signed contracts	1 (no assets) — 10 (fully derisked)
Promotion Intensity	Volume of IR marketing, press release cadence, retail/message-board buzz relative to actual operational progress	1 (no promotion) — 10 (aggressive promotion)

Quadrant Label	What It Means
Market Leader / Catalyst Play	High asset quality + high promotion — the market is watching and the company is delivering
Hidden Value / Deep Value	High asset quality + low promotion — real assets, flying under the radar
Pure Promote / Pump Risk	Low asset quality + high promotion — more marketing than substance
Zombie Stock / Dormant	Low asset quality + low promotion — neither delivering nor promoting

Note: Scores use a 1-10 scale. A score of 6 or above is classified as "High"; 5 or below is "Low."

The Bottom Line

August 6 was an earnings-driven day in micro-cap land. The indexes held up reasonably well — the Russell Microcap and Dow Jones Select MicroCap had been on a tear through early August, and a modest pullback is healthy after a 58% one-year run. The real story was at the individual stock level, where Q2 earnings separated the winners from the losers in brutal fashion.

For investors tracking the seven benchmarks we outlined in our July 14 landscape piece, the key trend remains: U.S. micro-caps are outperforming global peers, and within the U.S., the less-filtered Russell Microcap is outpacing the quality-screened Dow Jones Select MicroCap. The MSCI indexes, which report monthly, will give us a clearer global picture when the August review lands on the 12th.

Tomorrow brings three biotech IPOs to watch — Vogenx (VOGX), BlossomHill (BLSM), and Latigo (LTGO) — plus the Vogenx first-day trading recap after the bell closes. The micro-cap calendar is getting crowded, and that's exactly what a healthy market looks like.

---

Important Disclosure and Disclaimer

This publication is provided solely for general educational and informational purposes. Nothing contained in this publication constitutes, or should be construed as, investment, financial, legal, accounting, or tax advice; a recommendation or endorsement of any security, issuer, transaction, or investment strategy; or personalized advice based on any reader's particular financial circumstances.

This publication does not constitute an offer to sell, a solicitation of an offer to buy, or an invitation to enter into any transaction involving securities. Any offer or sale of securities may be made only through applicable offering documents and in accordance with applicable federal and state securities laws.

The Daily MicroCap and Eliakim Capital are not registered broker-dealers and do not execute securities transactions, accept investor funds, or provide brokerage services. Unless separately and expressly disclosed, neither The Daily MicroCap nor Eliakim Capital is acting as an investment adviser to any reader, and no advisory, fiduciary, attorney-client, or other professional relationship is created by this publication.

Information contained herein may be obtained from issuers, public filings, press releases, third-party sources, or other materials believed to be reliable; however, its accuracy, completeness, timeliness, and reliability are not guaranteed, and the information may not have been independently verified. Opinions and estimates are made as of the publication date and may change without notice.

Any statements regarding anticipated events, business prospects, financial performance, valuation, market opportunities, or future results are forward-looking and inherently uncertain. Actual outcomes may differ materially due to known and unknown risks.

Microcap and emerging-company securities can be highly speculative, volatile, illiquid, and subject to substantial dilution, limited publicly available information, and the risk of a complete loss of invested capital. Readers must conduct their own independent investigation and consult appropriately licensed financial, legal, and tax professionals before making any investment decision.

Neither The Daily MicroCap nor Eliakim Capital received compensation from the issuer for preparing or distributing this article.

Past performance is not indicative of future results. No representation or warranty is made regarding any investment outcome.

---

Todd Colpron is the Managing Partner of Eliakim Capital, a private investment and strategic advisory firm that invests its own capital and co-invests with a family office.